Clinical Trials · NCT06762314
Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Mostafa Bahaa
- Enrollment
- 114
- Start date
- Jan 2025
- Locations
- 1 site, Egypt
- Primary endpoint
- The primary outcome of this trial is the change in glycated haemoglobin from baseline after 3 months of treatment.